Glenmark's IGI to Present Updated ISB 2001 Multiple Myeloma Data at ASH
Glenmark Pharmaceuticals Ltd 路 Press Release 路 05 Nov 2026, 1:12 am
Glenmark's IGI to Present Updated ISB 2001 Multiple Myeloma Data at ASH Ichnos Glenmark Innovation announced an oral presentation of updated Phase 1 TRIgnite-1 data for ISB 2001 (ABBV-2001) at the 68th ASH Annual Meeting on 12th Dec'26. The investigational, first-in-class CD38 脳 BCMA 脳 CD3 trispecific T-cell engager targets relapsed/refractory multiple myeloma. New findings show robust efficacy and tolerability across longer dose-escalation follow-ups and early dose-expansion cohorts in heavily pretreated patients. ISB 2001 is being co-developed under an exclusive global licensing pact formed with AbbVie in Jul'25.
Original exchange filing (PDF)
More announcements from Glenmark Pharmaceuticals Ltd
- Ichnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301 路 18 Nov 2026
- Glenmark Pharmaceuticals Inc., USA Launches Authorised Generic of INLYTA (axitinib) Tablets, 1 mg and 5mg 路 16 Nov 2026
- Schedule of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Initmation of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Intimation of Schedule of Analyst / Institutional Investor Meetings 路 10 Nov 2026
- Transcript of the Earnings Call 路 09 Nov 2026
- Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 路 06 Nov 2026
